2023
So Now We Know—Reflections on the Extent of Resection for Stage I Lung Cancer
Detterbeck F, Ely S, Udelsman B, Blasberg J, Boffa D, Dhanasopon A, Mase V, Woodard G. So Now We Know—Reflections on the Extent of Resection for Stage I Lung Cancer. Clinical Lung Cancer 2023, 25: e113-e123. PMID: 38310034, DOI: 10.1016/j.cllc.2023.12.007.Peer-Reviewed Original ResearchStage I lung cancerI lung cancerSublobar resectionRecurrence-free survivalHealthy patientsLung cancerRecent trialsInadequate resection marginsLarge recent trialsAdditional randomized trialsHigh-level evidenceOverall survival differenceExtent of resectionLong-term outcomesLong-term resultsHigh locoregional recurrenceAspects of patientsLesser resectionsLocoregional recurrencePerioperative morbidityIntraoperative detailsLung functionResection extentResection marginsPostoperative changes
2022
A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 2: systematic review of evidence regarding resection extent in generally healthy patients
Detterbeck FC, Mase VJ, Li AX, Kumbasar U, Bade BC, Park HS, Decker RH, Madoff DC, Woodard GA, Brandt WS, Blasberg JD. A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 2: systematic review of evidence regarding resection extent in generally healthy patients. Journal Of Thoracic Disease 2022, 0: 0-0. PMID: 35813747, PMCID: PMC9264068, DOI: 10.21037/jtd-21-1824.Peer-Reviewed Original ResearchNon-randomized comparisonHealthy patientsResection extentIndividual patientsSystematic reviewStage I lung cancerI lung cancerStage I NSCLCCharacteristics of patientsPulmonary function testsLong-term outcomesRisk of recurrenceVideo-assisted approachSublobar resectionWedge resectionRandomized trialsFunction testsLung cancerResidual confoundingEffect modifiersShort-term benefitsLobectomyPatientsPubMed systematic reviewMargin distanceA guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 3: systematic review of evidence regarding surgery in compromised patients or specific tumors
Bade BC, Blasberg JD, Mase VJ, Kumbasar U, Li AX, Park HS, Decker RH, Madoff DC, Brandt WS, Woodard GA, Detterbeck FC. A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 3: systematic review of evidence regarding surgery in compromised patients or specific tumors. Journal Of Thoracic Disease 2022, 0: 0-0. PMID: 35813753, PMCID: PMC9264070, DOI: 10.21037/jtd-21-1825.Peer-Reviewed Original ResearchLimited pulmonary reserveLong-term outcomesResection extentNon-randomized comparisonPulmonary reserveOlder patientsIndividual patientsFavorable tumorsSystematic reviewStage I lung cancerFavorable long-term outcomeI lung cancerScreen-detected tumorsStage I NSCLCCharacteristics of patientsShort-term outcomesLesser resectionsPerioperative mortalityPulmonary functionSublobar resectionWedge resectionPatient selectionRandomized trialsLung cancerResidual confoundingA guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 4: systematic review of evidence involving SBRT and ablation
Park HS, Detterbeck FC, Madoff DC, Bade BC, Kumbasar U, Mase VJ, Li AX, Blasberg JD, Woodard GA, Brandt WS, Decker RH. A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 4: systematic review of evidence involving SBRT and ablation. Journal Of Thoracic Disease 2022, 0: 0-0. PMID: 35813762, PMCID: PMC9264060, DOI: 10.21037/jtd-21-1826.Peer-Reviewed Original ResearchLong-term outcomesNon-randomized comparisonIndividual patientsSystematic reviewStage I lung cancerI lung cancerCharacteristics of patientsStage I NSCLCPulmonary function testsMinority of patientsShort-term outcomesStereotactic body radiotherapyThermal ablationLate toxicityPulmonary functionRandomized trialsFunction testsAdjusted comparisonsBody radiotherapyLung cancerResidual confoundingEffect modifiersShort-term benefitsPatientsPubMed systematic reviewA guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation— part 1: a guide to decision-making
Detterbeck FC, Blasberg JD, Woodard GA, Decker RH, Kumbasar U, Park HS, Mase VJ, Bade BC, Li AX, Brandt WS, Madoff DC. A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation— part 1: a guide to decision-making. Journal Of Thoracic Disease 2022, 0: 0-0. PMID: 35813719, PMCID: PMC9264102, DOI: 10.21037/jtd-21-1823.Peer-Reviewed Original ResearchLong-term outcomesIndividual patientsHealthy patientsLung cancerFavorable tumorsStage I lung cancerBetter long-term outcomesI lung cancerStage I NSCLCOlder patientsPatient selectionPoint of careSurgical approachClinical careEffect modifiersTreatment selectionPatientsTreatment approachesPatient valuesClinical judgmentSystematic reviewRelevant outcomesLong-term differencesAvailable evidenceShort-term differences
2021
Resectability, Recurrence, and Risk Stratification of Giant Solitary Fibrous Tumors in the Thoracic Cavity
Woodard GA, Fels Elliott DR, Yap A, Haro GJ, Kratz JR, Mann MJ, Jones KD, Jablons DM. Resectability, Recurrence, and Risk Stratification of Giant Solitary Fibrous Tumors in the Thoracic Cavity. Annals Of Surgical Oncology 2021, 28: 4953-4959. PMID: 33728541, DOI: 10.1245/s10434-021-09757-7.Peer-Reviewed Original ResearchConceptsSingle-institution reviewInstitution reviewFibrous tumorThoracic cavityLong-term survival dataGiant solitary fibrous tumorBackgroundSolitary fibrous tumorsKaplan-Meier analysisPredictors of recurrenceRare mesenchymal tumorLong-term outcomesRisk of recurrenceMajority of tumorsSolitary fibrous tumorLong-term survivalSFT recurrencePathologic characteristicsRisk stratificationTumor sizeMesenchymal tumorsRisk factorsTumor necrosisVisceral pleuraClinical informationRecurrence